4 completed, 3 active not recruiting, 1 terminated. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Active not recruiting 3, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow KRAS Gene Mutation: new trials by email Literature Review of KRAS Gene Mutation trials Research Report on KRAS Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas TVB-2640 - KRAS Gene Mutation | Phase 2 | Active not recruiting | David E Gerber | 18 | 2019-09-11 | 2026-05-22 |
| Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer SHR-1210, Apatinib, Pemetrexed - NSCLC Stage IV, KRAS Gene Mutation | Phase 2 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 25 | 2019-07-11 | 2025-07-04 |
| A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance] - Solid Tumors, NSCLC | Phase 1 / Phase 2 | Completed | Calithera Biosciences, Inc | 53 | 2019-06-25 | 2022-09-19 |
| Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation Onvansertib, Bevacizumab, FOLFIRI - Metastatic Colorectal Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Cardiff Oncology | 68 | 2019-06-24 | 2025-03-04 |
| Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Trametinib 0.5 mg, Trametinib 1 MG, Trametinib 1.5 MG - Non Small Cell Lung Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 12 | 2018-10-09 | 2025-05-16 |
| Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Methotrexate, Pharmacokinetic Study, Regorafenib - KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Completed | Stanford University | 22 | 2018-08-14 | 2023-08-01 |
| Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer Laboratory Biomarker Analysis, Panitumumab, Trametinib - EGFR NP_005219.2:p.S492R, KRAS Gene Mutation | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 59 | 2017-12-29 | 2026-07-16 |
| Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer Docetaxel, Laboratory Biomarker Analysis, Trametinib - KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2016-07-18 | 2026-11-13 |
Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (2) · Brain Neoplasms (1)
Neoplasms (6) · Neoplasms by Site (6) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Lung Neoplasms (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2)
trametinib (3) · Bevacizumab (1) · CB-839 (1) · Carboplatin (1) · Docetaxel (1) · IFL protocol (1) · Methotrexate (1) · Panitumumab (1) · Pemetrexed (1) · Pharmacogenomic Variants (1) · TVB-2640 (1) · Tablets (1) · apatinib (1) · camrelizumab (1) · merphos (1)
Calithera Biosciences, Inc (1) · Cardiff Oncology (1) · David E Gerber (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Stanford University (1)
United States (7) · China (1)
Christine Parseghian (1) · David Gerber, MD (1) · Emil Kuriakose, MD (1) · Heather Wakelee (1) · Jianjun Zou, MD, PhD (1) · Kathryn Arbour, MD (1) · Shirish M Gadgeel (1) · Shun Lu, MD, PhD (1)
PMID 34646387, PMID 37233987, PMID 38231047, PMID 39475591
U10CA180888 (1)